SCHEMBL571389

SCHEMBL571389

CC(=O)[C@@]1(OC(=O)CBr)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.77
NR3C1 P04150 5/20 0.77
SMN1; SMN2 Q16637 5/20 0.77
CYP3A4 P08684 4/20 0.77
PGR P06401 4/20 0.77
MEN1 O00255 3/20 0.77
KMT2A Q03164 3/20 0.77
HIF1A Q16665 3/20 0.77
ADORA3 P0DMS8 2/20 0.77
MAPT P10636 2/20 0.77
SLC6A3 Q01959 2/20 0.77
NPSR1 Q6W5P4 2/20 0.77
HPGD P15428 1/20 0.77
MLNR O43193 1/20 0.77
NR1I2 O75469 1/20 0.77
HTT P42858 1/20 0.77
PDE4D Q08499 1/20 0.77
PDE3A Q14432 1/20 0.77
AR P10275 3/20 0.69
SHBG P04278 5/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11515560 0.92 NR3C1 (0.86) LMNANR3C1SMN1; SMN2CYP3A4PGR
SCHEMBL11511136 0.91 LMNA (0.78) LMNANR3C1SMN1; SMN2CYP3A4PGR
SCHEMBL6801424 0.91 AR (0.82) LMNANR3C1SMN1; SMN2CYP3A4PGR
SCHEMBL11510625 0.90 LMNA (0.77) LMNANR3C1SMN1; SMN2CYP3A4PGR
SCHEMBL11510015 0.90 LMNA (0.77) LMNANR3C1SMN1; SMN2CYP3A4PGR
SCHEMBL20101055 0.89 NR3C1 (0.88) LMNANR3C1SMN1; SMN2CYP3A4PGR
SCHEMBL260024 0.89 SMN1; SMN2 (0.74) LMNANR3C1SMN1; SMN2CYP3A4PGR
SCHEMBL13941349 0.89 SMN1; SMN2 (0.74) LMNANR3C1SMN1; SMN2CYP3A4PGR
SCHEMBL29766827 0.89 SMN1; SMN2 (0.74) LMNANR3C1SMN1; SMN2CYP3A4PGR
SCHEMBL27048175 0.89 SMN1; SMN2 (0.74) LMNANR3C1SMN1; SMN2CYP3A4PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140234271-A1 COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS THE HOSPITAL FOR SICK CHILDREN (CA) 2014-08-21 US disclosed
US-8748177-B2 Compositions for proliferation of cells and related methods THE HOSPITAL FOR SICK CHILDREN (CA) 2014-06-10 US disclosed
EP-2598150-A2 COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS The Hospital For Sick Children (CA) 2013-06-05 EP disclosed
WO-2012018643-A2 COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS THE HOSPITAL FOR SICK CHILDREN (CA) 2012-02-09 WO disclosed
US-20110301105-A1 COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS THE HOSPITAL FOR SICK CHILDREN (CA) 2011-12-08 US disclosed
WO-2010039679-A1 COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS THE HOSPITAL FOR SICK CHILDREN (CA) 2010-04-08 WO disclosed
US-4177269-A ANTITUMOR AGENTS AKTIEBOLAGET LEO (SE) 1979-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140234271-A1 COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS MKI67, KRT18, PROX1 LMNA 2509/4885NR3C1 3193/4885SMN1; SMN2 4188/4885
US-20110301105-A1 COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS MKI67, KRT18, PROX1 LMNA 2509/4885NR3C1 3193/4885SMN1; SMN2 4188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.